Verrica Pharmaceuticals Inc. (VRCA) Q1 2025 Earnings
Verrica Pharmaceuticals Inc. reported Q1 2025 revenue of $3.4M (-10.1% YoY), missed analyst consensus of $3.5M by $93.7K. Diluted EPS came in at $-1.00 (-163.2% YoY), beat the $-1.40 consensus by $0.40.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Verrica Pharmaceuticals Inc.'s Q1 2025 earnings report.
Verrica Pharmaceuticals Inc. (VRCA) reported Q1 2025 earnings on May 13, 2025 after market close.
Verrica Pharmaceuticals Inc. reported revenue of $3.4M and diluted EPS of $-1.00 for Q1 2025.
Revenue missed the consensus estimate of $3.5M by $93.7K. EPS beat the consensus estimate of $-1.40 by $0.40.
Compared to the same quarter a year prior, revenue declined 10.1% from $3.8M a year earlier and diluted EPS declined 163.2% from $-0.38.
You can read the 10-Q periodic report (0000950170-25-070452) directly on SEC EDGAR. The filing index links above go to sec.gov.